Ra Capital Management, L.p. bought $55M of WVE
director, owner at Wave Life Sciences Ltd.. 8,772,496 shares at an average of $6.23, traded Mar 26, 2026, filed Mar 30, 2026.
Score components
- +15RoleDirector
- +25Trade size$54.6M at market
- +6Relative to holdingsHoldings up 48%
- +8Price context71% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -38% over 3 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +6.5%, 3m -14.2%, 6m -44.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000297, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | POpen-market purchase Ordinary Sharesindirect: See footnotes | +4,954,558 | $6.06 | $30M | 23,157,567 | Mar 30, 2026 |
| Mar 26, 2026 | POpen-market purchase Ordinary Sharesindirect: See footnotes | +351,224 | $6.38 | $2.2M | 23,508,791 | Mar 30, 2026 |
| Mar 27, 2026 | POpen-market purchase Ordinary Sharesindirect: See footnotes | +2,495,623 | $6.43 | $16M | 26,004,414 | Mar 30, 2026 |
| Mar 30, 2026 | POpen-market purchase Ordinary Sharesindirect: See footnotes | +971,091 | $6.50 | $6.3M | 26,975,505 | Mar 30, 2026 |
Related signals
Other insiders at Wave Life Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Wave Life Sciences Ltd. | Adrian Rawcliffe director | $67k 12,700 shares | -100% | |
| 15Weak | Wave Life Sciences Ltd. | Ken Takanashi director | $23k 3,864 shares | -16% | |
| 10Weak | Wave Life Sciences Ltd. | Aik Na Tan director | $2,596 432 shares | -2% | |
| 6Weak | Wave Life Sciences Ltd. | Heidi L Wagner director | $42k 7,000 shares | -13% | |
| 8Weak | Wave Life Sciences Ltd. | Chris Francis See Remarks | $500k 33,194 shares | -42% | |
| 51Moderate | Wave Life Sciences Ltd. | Paul Bolno President and CEO | $141k 10,480 shares | -4% | |
| 35Weak | Wave Life Sciences Ltd. | Chris Francis See Remarks | $25k 1,883 shares | -3% | |
| 44Moderate | Wave Life Sciences Ltd. | Kyle Moran Chief Financial Officer | $48k 3,588 shares | -3% | |
| 36Weak | Wave Life Sciences Ltd. | Chandra Vargeese See Remarks | $43k 3,228 shares | -1% | |
| 1Weak | Wave Life Sciences Ltd. | Chris Francis See Remarks | $150k 9,375 shares | -27% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.